在第三季度,Invenomic增加了其DENTSPLY SIRONA股份的48.7%,该公司报告了轻微的收益缺失,并预计2026年每股收益为1.40美元-1.50美元. Invenomic boosted its DENTSPLY SIRONA stake 48.7% in Q3; company reported slight earnings miss and projected 2026 EPS of $1.40–$1.50.

在第三季度,Invenomic Capital Management LP在DENTSPLY SIRONA的股份增长了48.7%,成为该公司第二大股份,而Crawford Investment Counsel收购了87,007股股票. Invenomic Capital Management LP boosted its stake in DENTSPLY SIRONA by 48.7% in Q3, making it the firm’s second-largest holding, while Crawford Investment Counsel acquired 87,007 shares. 该公司报告Q4收入为每股0.27美元,略低于28美元的估计数,收入为9.61亿美元,比上一年增加6.2%。 The company reported Q4 earnings of $0.27 per share, slightly below the $0.28 estimate, with revenue of $961 million, up 6.2% year-over-year. James D. Forbes董事和Gregory T. Lucier董事每人购买股票,增加了他们的股份。 Directors James D. Forbes and Gregory T. Lucier each bought shares, increasing their stakes. DENTSPLY SIRONA市值为23.1亿美元，预计2026财年每股收益为140至1.50美元。 DENTSPLY SIRONA, with a market cap of $2.31 billion, projects FY 2026 EPS of $1.40–$1.50. 分析员按照14.42美元的平均价格目标对库存进行“等待”评级。 Analysts rate the stock a "Hold" with a $14.42 average price target.